104246-33-5

Upstream product

• 127-69-5 sulfisoxazole 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 1449513-52-3 N₄-(4-bromobenzylidene)hydrazinoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-53-4 N₄-(4-hydroxybenzylidene)hydrazinoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-54-5 N₄-(4-nitrobenzylidene)hydrazinoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-61-4 N₄-(2-phenyl-3-chloro-4-oxoazetidin-1-yl)aminoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-62-5 N₄-[2-(4-fluorophenyl)-3-chloro-4-oxoazetidin-1-yl]aminoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-63-6 N₄-[2-(4-chlorophenyl)-3-chloro-4-oxoazetidin-1-yl]aminoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-64-7 N₄-[2-(4-bromophenyl)-3-chloro-4-oxoazetidin-1-yl]aminoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-65-8 N₄-[2-(4-hydroxyphenyl)-3-chloro-4-oxoazetidin-1-yl]aminoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-66-9 N₄-[2-(4-nitrophenyl)-3-chloro-4-oxoazetidin-1-yl]aminoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1447968-83-3 C₁₃H₁₇N₅O₄S 
• 1449513-49-8 N₄-(benzylidene)hydrazinoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-50-1 N₄-(4-fluorobenzylidene)hydrazinoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 
• 1449513-51-2 N₄-(4-chlorobenzylidene)hydrazinoacetylamino-N₁-(3,4-dimethyl-1,2-oxazol-5-yl)benzensulfonamide 

Relevant academic research and scientific papers

Design and synthesis of new sulfonamides–based flt3 inhibitors

Background: Flt3 is an oncogenic kinase involved in different leukemias. It is most prominently associated with acute myeloid leukemia (AML). Flt3-specific inhibitors have shown promising results in interfering with AML. Methods: The crystallographic structures of two inhibitors complexed within Flt3, namely, quizartinib and F6M, were used to guide the synthesis of new sulfonamide-based Flt3 inhibitors. Results: One of the prepared compounds showed low micromolar anti-Flt3 bioactivity, and interestingly, low micromolar bioactivity against the related oncogenic kinase VEGFR2.

New antimicrobial chitosan derivatives for wound dressing applications

Chitosan is a non-toxic, biocompatible, biodegradable natural cationic polymer known for its low imunogenicity, antimicrobial, antioxidant effects and wound-healing activity. To improve its therapeutic potential, new chitosan-sulfonamide derivatives have

Synthesis and biological evaluation of new 2-azetidinones with sulfonamide structures

New series of N-(arylidene)hydrazinoacetyl sulfonamides 4a1-6, 4b1-6 and N-(4-aryl-3-chloro-2-oxoazetidin-1-yl)aminoacetyl sulfonamides 5a1-6, 5b1-6 were synthesized. The structures of the new derivatives was co